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Abstract 
Transforming Growth Factor-beta (TGF-β) is a pro-sclerotic cytokine widely associated with the 
development of fibrosis in diabetic nephropathy. Central to the underlying pathology of 
tubulointerstitial fibrosis is epithelial-to-mesenchymal transition (EMT), or the trans-differentiation of 
tubular epithelial cells into myofibroblasts.  This process is accompanied by a number of key 
morphological and phenotypic changes culminating in detachment of cells from the tubular basement 
membrane and migration into the interstitium. Ultimately these cells reside as activated 
myofibroblasts and further exacerbate the state of fibrosis. A large body of evidence supports a role 
for TGF-β and downstream Smad signaling in the development and progression of renal fibrosis. Here 
we discuss a role for TGF-β as the principle effector in the development of renal fibrosis in diabetic 
nephropathy, focusing on the role of the TGF-β1 isoform and its downstream signaling intermediates, 
the Smad proteins. Specifically we review evidence for TGF-β1 induced EMT in both the proximal 
and distal regions of the nephron and describe potential therapeutic strategies that may target TGF-β1 
activity. 
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Introduction: 
Diabetic nephropathy (DN) is the single commonest cause of entry into the renal replacement therapy 
programme, and with the incidence of the disease doubling in the past decade DN now accounts for 
approximately 50% of those patients presenting with end-stage renal failure [1]. Although the 
aetiology of Type I and Type II diabetes is notably distinct, glucose-evoked changes in renal 
physiology are almost indistinguishable and often lead to complete destruction of kidney function 
prompting the need for dialysis or transplantation therapy [2]. Multiple structural and functional 
changes are associated with the disease, specifically in the glomerulus, tubulointerstitium and 
vasculature [3], where glycaemic injury includes structural abnormalities ranging from hypertrophy, 
thickening of the glomerular basement membrane, tubular atrophy and interstitial fibrosis [4]. These 
changes contribute to increased glomerular filtration rate, proteinuria, systemic hypertension and the 
loss of renal function [4]. Histologically, DN is characterised by an accumulation of extracellular 
matrix (ECM) in both the glomerular mesangium and tubular interstitum, culminating in excessive 
renal scarring and a decline in excretory function [4-7]. Renal fibrosis is evidenced by 
glomeruosclerosis, tubulinterstitial fibrosis (TIF), infiltration of inflammatory mediators and the 
activation of alpha-smooth muscle actin (α-SMA)-positive myofibroblasts [6][8]. Of these fibrotic 
changes, tubulointerstitial fibrosis is the key underlying pathology and represents the final common 
pathway for End-Stage Renal Disease (ESRD). Understanding those mediating signals which regulate 
deposition of fibrotic material in the interstitium is critical to future identification and development of 
site specific therapeutics which may alleviate this damage.  Central to TIF is tubular epithelial-to-
mesenchymal transition (EMT), or the transdifferentiation of tubular epithelial cells into 
myofibroblasts [9-10]. In DN, EMT occurs as cells attempt to evade apoptosis as a consequence of 
exposure to pathophysiological stimuli [11-12]. Cells undergo transition in a process that involves the 
generation of active myofibroblasts, excessive deposition of ECM and destruction of normal tissue 
architecture [13-14]. The ability to switch phenotype stems from a unique plasticity of epithelial cells 
that has, up until recently, been universally accepted as the sole driving force behind the generation of 
interstital fibroblasts in kidney disease. EMT of proximal tubule cells (PTC) has been clearly 
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documented in DN, with overwhelming evidence implicating the cytokine Transforming Growth 
Factor-beta 1 (TGF-β1) as the key mediator [15-16]. Our knowledge of the pathology of TGF-β1 in 
the kidney is extensive however, the majority of this research is dedicated to exploring the 
consequences of TGF-β1 signalling in glomerular cells, mesangial cells or podocytes. The aim of the 
current review is to discuss a role for TGF-β1 in DN, specifically in the proximal tubule and the 
collecting duct, where potential therapeutic strategies to inhibit renal fibrogenesis in diabetes may be 
unearthed.  
 
TGF-β1 as a molecular mediator of renal fibrosis in Diabetic Nephropathy:  
Deposition of ECM is required for normal wound healing in response to renal injury, but the 
excessive deposition of matrix is the pathological hallmark of renal fibrosis and occurs when cells of 
the nephron over compensate in an attempt to maintain both cell integrity and function. A tight 
balance between synthesis and breakdown of matrix proteins is therefore required to maintain normal 
function. One way to control this balance is via the release of mediators from inflammatory or 
connective tissue cells which act to regulate collagen and matrix metalloproteinase (MMP) 
production. Loss of this regulation can ultimately tip the balance from repair to injury culminating in a 
build up of fibrotic material and scar formation. 
Diagnosed by glomerulosclerosis, tubulointerstitial fibrosis, inflammatory filtration, and loss of renal 
architecture [17], renal fibrosis develops in response to an accumulation of ECM. In DN, progressive 
tubulointerstitial fibrosis represents the final common pathway of chronic renal failure and is a 
consequence of increased production and altered degradation of ECM components.  In diabetes, 
hyperglycaemia is the driving force behind the majority of these pathways and the inevitable build up 
of fibrotic material [16][18]. A decline in the number of nephrons parallels increased fibrosis as 
interstitial scarring replaces the spaces left by nephrons lost in this pathological process; the net result 
is impaired renal function. 
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Although more than a dozen fibrogenic factors affect renal function, it is widely recognised that the 
pro-sclerotic cytokine TGF-β1 and its downstream Smad signalling cascade, represents the 
predominant pathway orchestrating renal fibrosis [19][20]. Abnormalities in TGF-β1 have been linked 
to a variety of disorders, including autoimmune diseases, malignancies, and chronic renal disease 
[21]. Indeed, the up-regulation of TGF-β appears prevalent in all forms of chronic kidney disease 
(CKD) in both animal models and humans. Increased expression of TGF-β receptors have been 
described in experimental models of renal disease including; membranous nephropathy, obstructive 
nephropathy, and DN [21], whilst animal models of spontaneous diabetes (BB rat and NOD mouse) 
demonstrate increased TGF-β1 mRNA expression within 3-7 days of the onset of hyperglycaemia 
[22]. In the streptozotocin (STZ)-induced diabetic rat, mRNA expression for both TGF-β1 and the 
type II TGF-β receptor are increased within 3days following exposure to hyperglycamia [22]. Initiated 
in response to the actions of numerous circulating signalling molecules, hyperglycaemia drives the 
production of various downstream mediators of TGF-β. These downstream effector molecules include 
Advanced Glycation End products (AGEs), protein kinase C (PKC) and diacylglyerol (DAG). 
Together they instigate excess deposition of ECM [16][18][23]. Glucose-induced TGF-β1 mediated 
increases in ECM have been reported in cultured mesangial cells [24], podocytes [25] and tubular 
epithelial cells [26], the cumulative effect of which is destruction of the renal parenchyma. A recent 
study by Reiniger et al (2010) demonstrated that removal of the AGE receptor in the diabetic OVE26 
mouse, attenuated the degree of glomerulosclerosis with a concomitant improvement in renal function 
[27], whilst over-expression of PKC, has been shown to exert fibrotic effects in human proximal 
tubular cells [28]. Patient studies also implicate TGF-β1 with fibrosis in DN and individuals with both 
type I and type II diabetes mellitus exhibit enhanced production of TGF-β1 in their kidneys, 
expression of which closely correlates to the degree of glycaemic control [29-30]. 
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The role of TGF-β1 signalling in renal fibrosis: 
The TGF-β superfamily is comprised of secreted peptides subdivided into four main subgroups: the 
mullerian inhibitory substance (MIS) family, the inhibin/activin family, the bone morphogenetic 
protein (BMP) family and the TGF-β family [31]. Of these secreted peptides, all but the MIS family; 
are commonly associated with mammalian development, homeostasis and pathobiology. A broad 
spectrum cytokine, TGF-β regulates many fundamental biological processes including cell growth, 
differentiation, adhesion, proliferation tissue repair and apoptosis [32-33]. Of the five distinct 
isoforms which have been identified in vertebrates, only three have been shown to be expressed in 
mammals [34]. These isoforms exhibit ubiquitous levels of expression and act to evoke a response via 
the initiation of several intracellular signalling cascades, including the small mothers against 
decapentaplegic (SMADs) and mitogen activated protein kinases (MAPK), such as extracellular 
regulated kinase (ERK), p38 and Jun Kinase [35]. More recently, a study performed by Nyhan and 
colleagues demonstrated a role for a separate signalling cascade. Using proximal tubule cell line 
models, HK2 and RPTEC cells, they demonstrated that the Jagged/Notch signalling pathway is 
activated in response to TGF-β1. Furthermore, the cytokine-evoked changes in Jagged 1 expression 
preceeded EMT associated gene changes in both E-cadherin and vimentin, effects which appeared to 
be dependent on Smad3 activity [36]. Therefore, TGF-β1 can modulate transcription of multiple target 
genes through the activation of at least one, or a cross talk of multiple signaling pathways.  
 The TGF-β1 gene encodes a 390 amino acid precursor molecule that is composed of a signal 
peptide, the active TGF-β1 molecule and a latency associated peptide (LAP). Only when the signal 
peptide is proteolytically cleaved from the TGF-β1 gene product is an inactive latent TGF-β1, 
covalently bound with the LAP, released [37]. Dissociation of the covalent bond depends on 
environmental changes in pH, but ultimately TGF-β1 is released from the latent complex, enabling 
mature, active TGF-β1 to bind to its cell surface receptors [38]. The TGF-β receptor is a heteromeric 
trans-membrane complex consisting of both the TGF-β receptor II (TβRII) and TGF-β receptor type I 
(TβRI), the latter includes activin-like kinase (ALK) receptors. Unlike many membrane bound 
complexes which possess tyrosine kinase activity, the TGF-β receptors possess serine/threonine 
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kinase activity. Binding of TGF-β1 to the TBRII receptor is accompanied by phosphorylation and 
subsequent activation of the type I receptor within its cytoplasmic domain.  This association results in 
the downstream phosphorylation and activation of its classic signaling mediators, Smad2 and Smad3 
[39-40]. Smads are subdivided into three classes; Receptor regulated (R) Smads (Smad1, 2, 3, 5 and 
8), the Common (Co) Smads (Smad4) and the Inhibitory (I) Smads (Smad6 and 7) [39]. Following 
TβRII activation, R-Smads form oligomeric complexes with the common Smad (Co-Smad) prior to 
translocation into the nucleus and regulation of gene transcription (see figure 1) [39].  
 TGF-β/Smad signaling is stringently controlled within the cell and is regulated at both 
prereceptor and postreceptor stages through multiple levels of modulation. However, in many cell 
lines, TGF-β1 has the ability to regulate its own transcription through binding of an AP-1 
transcription factor complex to the TGF-β1 promoter [41-42] or through the involvement of a Smad3-
dependent signalling pathway [43]. Autoinduction of TGF-β1 is a well recognized phenomenon which 
has been described in a variety of cell types [42]. However, the significance of this may be tissue-
specific. The effect of auto-induction, whether beneficial or detrimental to the cell, depends on a 
scenario in which expression is upregulated. For example, TGF-β1 mRNA auto-induction is thought 
to have a beneficial role in cardiac wound healing after ischemic injury [44] , whilst auto-induction of 
TGF-β1 at the site of injury in the proximal tubule may result in a positive feedback, where sustained 
cytokine production may accelerate EMT and increase the generation of myofibroblasts thus 
promoting and exacerbating fibrosis. A correlation between Smads and AP-1 has also been suggested 
following elegant studies performed in a mouse model of unilateral ureteric obstruction and in 
fibroblasts obtained from Smad2 and Smad3 knockout animals [45-46]. These studies confirmed not 
only a correlation between Smad signalling and TGF-β1 auto-induction, but further demonstrated that 
the relationship depended on the presence and activation of Smad3. These observations agree with 
previous studies and support a role for Smad signalling in the development of renal fibrosis [47].  
 The majority of TGF- s regulated in EMT rely on Smad3-dependent 
transcriptional regulation [45]. Recent studies in renal proximal tubule cells demonstrated angiotensin 
II-induced tubular EMT was Smad3-dependent [48], whilst (β)1-integrin gene expression, a potential 
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therapeutic target of renal fibrosis is also up-regulated in both unilateral obstruction and in chronic 
tubulointerstitial fibrosis via a Smad3-dependent mechanism [49]. Despite the predominant 
involvement of Smad3, a role Smad2 should not be discounted [50]. Differential roles for both Smad2 
and Smad3 have been identified [51]. Smad3-dependent reduction of the cell adhesion protein E-
cadherin in human proximal tubular cells (hPTC) is paralleled by a Smad2-dependent induction of 
metallomatrix proteinase 2 [52]. Microarray analysis of TGF-β1-induced EMT in mouse and human 
epithelial cells demonstrates a critical requirement for Smad signalling in the regulation of all tested 
target genes [52] and an acute need for stringent control of Smad signalling in order to protect the 
cells from unwanted responses to TGF-β. Indeed, a safeguard mechanism exists in the form of 
inhibitory Smads and transcriptional co-repressors [53]. However, the level of hyperactive Smad 
signalling observed in certain types of renal disease reflects abberant levels of both Smad co-
repressors and their subsequent regulators [54-55]. The inhibitory Smads (Smad6 and Smad7) inhibit 
R-Smad phosphorylation by blocking their access to TβRI, &/or by promoting the degradation of the 
receptor complexes. Smad7 represents a general antagonist of both TGF-β1 and BMP signalling, with 
reports showing that induction of Smad7 blocks tubular EMT and the development of fibrotic lesions 
[56-57]. Smad6 appears to play a more specific role in the Bone Morphogenic Pathway (BMP) [58-
60]. 
 The co-repressors SnoN (Ski-related novel gene, non Alu-containing), Ski (Sloan-Kettering 
Institute proto-oncogene), and TGIF (TG-interacting factor) prevent gene transcription through 
inhibition of R-Smads [61]. Since these antagonists are critical in ensuring the regulation of Smad-
mediated gene transcription, a fine balance must be achieved in order to match cellular demands. It is 
of no surprise that diminished levels of co-repressors are observed in animal models of obstructive 
nephropathy and diabetes [67]. Smad ubiquitination regulatory factor-2 (Smurf2) is an ubiquitin ligase 
that specifically targets certain members of Smad proteins for degradation, including Ski, SnoN and 
TGIF [63]. The close association between Smurf2 expression and enhanced SnoN degradation [62] 
suggests that the dysregulation of Smurf2 is most likely to affect profibrotic TGF-β/Smad signalling 
and may contribute to the development and progression of renal fibrotic diseases in humans [63]. A 
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role for Smurf2 in the degradation of inhibitory Smad7, an event paralleled by increased tubular EMT 
has recently been reported [48]. 
 
EMT in the kidney 
Renal tubules are developmentally derived from the metanephric mesenchyme through a process 
termed mesenchymal-to-epithelial transdifferentiation (MET). This cellular differentiation is fluid and 
cells retain the ability to revert back to their original mesenchymal phenotype through EMT. 
Commonly associated with epithelia of embryonic origin, this plasticity is critical in early stages of 
development and is commonly referred to as type I EMT [64]. There are two further subtypes of 
EMT, type II and type III, the latter of which occurs in epithelial cancer cells that differ genetically 
and epigenetically from untransformed epithelial cells. In adults, EMT is associated with tissue injury 
and repair; a process instigated as the demand for fibroblasts and wound healing increases [68]. Type 
2 EMT is now used to categorise events that occur in epithelial cells following injury. As cells 
undergo Type 2 EMT they provide the interstitium with a new supply of fibroblasts. Furthermore, in 
an attempt to restore a healthy population of cells lining the tubular basement membrane (TBM)  
some epithelial cells are able to employ EMT as a means to migrate into damaged areas of the 
nephron prior to reconversion into an epithelial phenotype [64]. 
 In EMT, the loss of epithelial characteristics coincide with the acquisition of proteins 
associated with a mesenchymal phenoptye (See figure 2) These morphological and phenotypic 
changes occur at four different stages: (i) the loss of epithelial cell adhesion molecules such as 
Epithelial (E)-cadherin and zonula occludens protein ZO-1 are replaced by the (ii) mesenchymal 
markers α-SMA and the intermediate filament protein vimentin. The loss of cell adhesion is 
accompanied by (iii) cytoskeletal remodelling and morphological changes resulting in tubular 
basement membrane disruption. (iv). As myofibroblasts exhibit enhanced motility and increased 
proliferative and contractile capacity, these cells possess the ability to migrate from TBM into the 
interstium. This migratory capacity leads to increased deposition of the ECM and makes EMT pivotal 
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in the pathology of tubulointerstitial fibrosis. Normally, tubular epithelial cells form a highly coupled 
epithelial sheet held together by the adhesion molecule E-cadherin. Loss of E-cadherin expression 
occurs in the early stages of EMT and results in the dissociation of cells within the epithelial sheet 
[66]. Whether the loss of
 
E-cadherin is a consequence or a cause of EMT remains unknown. However, 
TGF-β1 is unable to initiate EMT without disrupting the integrity of cell-to-cell contact, indicating 
involvement
 
of E-cadherin in this TGF-β1-mediated process [67]. The loss of cell adhesion represents 
the beginning of a series of events culminating in transition from an epithelial-to-mesenchymal 
phenotype. Changes in E-cadherin are rapidly accompanied by an up-regulation of mesenchymal 
markers. Re-organisation of the actin cytoskeleton into stress fibres containing de novo expression of 
α-SMA is accompanied by an exchange of cytokeratin for vimentin filaments and the expression of 
fibroblast-specific-protein-1 (FSP1), a Ca
2+
-binding protein involved in motility, invasion, and tubulin 
polymerization. These morphological and phenotypic changes support matrix remodelling and 
migration across the TBM into the interstitial environment [68].  
 The migratory phenotype, used to define EMT remains controversial, especially in the context 
of fibrosis [69]. Loss of an epithelial phenotype can be clearly identified by a loss in the expression of 
specific epithelial proteins, in particular E-cadherin. Acquisition of a mesenchymal phenotype is more 
difficult to assign [70] and may explain why EMT is often over-looked in studies of renal disease. 
Classic markers used to de -SMA [71]. Whilst vimentin is not 
specific for fibroblastoid cells [72], staining of both vimentin and tubular β-catenin is currently being 
used clinically to assess early renal injury (clinical trial NCT#01079143) [73]. Although α-SMA 
represents the most commonly used marker in EMT, heterogeneity of expression means that this 
protein is not a definitive marker [74], and clarification of EMT in fibrosis should be regarded with 
caution, since confirmation of this phenotypic transformation appears to depend upon a complex 
interplay of events. The concept that cells of an epithelial origin are able to undergo a phenotypic 
transformation in response to pathophysiological stimuli and ultimately traverse the TBM has, up 
until recently, been universally accepted. However, there is now clinical evidence from biopsies of 
renal allografts suggesting that the changes in epithelial phenotype precede fibrosis [75]. 
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Consequently, the contribution of EMT to renal fibrosis in vivo and, more importantly, the exact 
origin of the myofibroblasts [76-77] has become an area of intense debate [78]. 
Type 2 EMT is commonly defined as the ability of adult epithelial cells to undergo dedifferentiation, 
traverse the TBM into the interstitium and transdifferentiate into a myofibroblast phenotype capable 
of synthesising and increasing the deposition of ECM. Ultimately the epithelium is replaced by 
mesenchymal cells and fibrous scar tissue. Whilst these activated myofibroblasts are commonly 
thought of as key effector cells in the pathogenesis of renal fibrosis, it is becoming increasingly clear 
that they originate from multiple lineages. This has subsequently led many to cast doubt over the 
contribution of EMT to renal fibrosis in vivo and more importantly, question the exact cell type 
involved [76-77]. An accumulating body of evidence suggests that cells contributing to this pool, may 
include local interstitial fibroblasts [79], pericytes [80][81] local mesenchymal stem cells [82] or the 
injured epithelium itself [10]. As a result of these studies, there is now considerable debate both for 
and against a role of EMT in renal fibrosis. These arguments are eloquently summarised in a recent 
article published in JASN where eminent leaders in the field (Michael Zeisberg and Jeremy Duffied) 
debate the case for EMT in fibrosis [83]. 
Until recently, support for the role of EMT in fibrosis was based upon the following observations: (1) 
Tubular epithelial cells transform into activated myofibroblasts in response to pathophysiological 
stimuli, e.g. TGF- 1, Connective Tissue Growth Factor (CTGF) and AGE products (2) Characteristic 
features of this phenotypic transition include the loss in expression of epithelial markers including E-
cadherin, Zo-1 and cytokeratin, with subsequent acquisition of mesenchymal markers, e.g. -SMA 
and FSP1. (3) The use of lineage tracking to confirm the epithelial origin of cells within a 
myofibroblast pool in various models of fibrosis [10] [84-88]. (4) Amelioration of fibrosis using 
therapies designed to target EMT [87]. Of these different types of studies, the most persuasive is 
genetic fate mapping, which allows for cells of the epithelium to be genetically tagged and mapped 
throughout a disease process. Pioneering work by Iwano et al employed fate mapping to establish a 
role for EMT in unilateral ureteral obstruction (UUO) [10]. However, there has been a dearth of 
follow up work of this type and the established mainstay criteria supporting a role for EMT in fibrosis 
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is usually based around determining morphological changes and establishing whether there are 
alterations in the expression of key epithelial/mesenchymal markers. Surprisingly, these studies fail to 
demonstrate complete EMT in which fibroblasts fully migrate and traverse the TBM. More commonly 
observed is the phenomenon known as partial EMT (p-EMT) in which cells express both epithelial 
and mesenchymal markers. This intermediate phenotype is of relevance because the acquisition of 
mesenchymal markers and expression of ECM proteins that occur early in EMT may be transient, 
occurring in cells exposed to the diabetic milieu and contributing to fibrosis [71][88]. The argument 
against the full phenotypic transformation has been fuelled by data from the Duffield group who 
suggest that not only is EMT unlikely to occur in vivo, but that vascular pericytes are the source of 
fibrosis generating myofibroblasts. Furthermore, they suggest that epithelial cells contribute to 
fibrosis through paracrine cell signalling [81][89].  
 
TGF-β1, EMT and fibrosis in diabetic nephropathy:  
 The original link between fibrosis and EMT was suggested 15years ago in a model of mouse 
anti-tubular membrane disease where it was observed that renal tubular epithelial cells were capable 
of expressing the FSP1 [87]. A role for EMT in the progression of CKD was later confirmed in a 
model of UUO using genetically tagged (Lac Z) proximal tubule cells. The authors demonstrated that 
of those matrix producing cells resident within the tubulointerstitial space, 36% were of epithelial 
origin and thus derived from renal tubular epithelium through EMT [10]. The underlying pathology of 
EMT has since been observed in renal biopsies from diseased kidney where the proportion of cells 
undergoing transition correlated to both the level of serum creatinine and the degree of interstitial 
fibrosis [88]. Evidence for EMT in vivo has since been described in various forms of of CKD, 
including diabetic nephropathy [89][90]. In diabetes, glomerular fibrosis is observed in the 
progression from incipient to overt nephropathy [6]. Whilst tubulointerstitial fibrosis can also present 
itself in these early stages, a build up of fibrotic material in the tubular interstitium tends to 
accompany disease progression, correlating with a gradual decline in renal function [6]. 
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Consequently, progressive tubulointerstitial fibrosis, in part mediated by EMT, represents the final 
common pathway leading to renal failure in diabetic nephropathy [7].  
 In models of renal disease, EMT occurs in response to hypoxia, reactive oxygen species, AGE 
and numerous pro-fibrotic cytokines, growth factors and metalloproteinases. Of these TGF-β1 
represents the principle candidate in the development and progression of fibrotic complications. A 
role for TGF- 1 induced EMT in the pathology of tubulointerstitial fibrosis in DN has been reported 
and histological examination of kidneys from diabetic animals and biopsies from patients with DN 
where phenotypic changes associated with EMT have been observed [89][91]. In a study by Burns et 
al, EMT was studied in a rat tubular epithelial cell line (NRK-529) and the STZ-induced Sprague 
Dawley rat [89]. Following incubation with TGF- 1, EMT in NRK-529 cells was confirmed by the 
altered expression of -SMA, Vimentin and E-cadherin, whilst Sprague Dawley rats exhibited 
increased renal gene expression of TGF- 1 at 32 weeks and enhanced -SMA and collagen with a 
concomitant decrease in E-cadherin expression compared to control [89]. Similar markers of EMT 
have also been observed in a variety of animal models, including STZ-treated Wistar Kyoto rats, 
Sprague Dawley rats and the STZ-Ren-2 rat [89-90][92]. 
 The existence of FSP1 in podocytes from patients with diabetes is most likely associated with 
induction of podocyte detatchment through EMT [91]. Depletion of glomerular podocytes is an 
important feature of progressive diabetic nephropathy. Although the most plausible explanation for 
this podocyte depletion is detachment from the glomerular basement membrane after cellular 
apoptosis, the mechanism is unclear. FSP1 is constitutively expressed in the cytoplasm of tissue 
fibroblasts or epithelial cells converted into fibroblasts by EMT. In a study performed by Yamaguchi 
et al, of 109 patients presenting with both Type 2 diabetes and diabetic nephropathy 35% were 
normoalbuminuric, 15% had microalbuminuria, 7% had macroalbuminuria and 43% had decreased 
kidney function. In biopsies from 43 of these patients it appeared that the number of FSP1 positive 
podocytes was significantly higher in individuals with macroalbuminuria as opposed to those 
presenting with normoalbuminuria (p=0.03). Furthermore, the number of FSP1 positive podocytes 
was larger in those glomeruli exhibiting diffuse mesangiopathy than in those with focal 
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mesangiopathy. FSP1-positive podocytes selectively expressed Snail and integrin-linked kinase, a 
known trigger for EMT. 
 Recently, a role for microRNAs in regulation of EMT in the diabetic kidney has been 
established. MicroRNAs (miRNAs) are endogenous non-coding RNA molecules, which function as 
negative regulators of gene expression [93]. miRNA 192 is expressed in both glomerular and tubular 
human kidney sections. Interest in this exciting area of research stems from the fact that miRNA 192 
is down-regulated in DN in response to TGF- , an event that correlates to increased fibrosis [94]. The 
link between a loss in miRNA 192 and the development of fibrosis in DN is thought to be a 
consequence of a loss of regulation of those genes involved in EMT, a concept recently supported by 
Wang et al [95]. Using rat proximal tubule cells, they demonstrated that both TGF- 1 and TGF- 2 
were able to induce EMT and fibrogenesis as a consequence of a loss in mir-200a expression. This 
loss in expression was shown to augment EMT induced fibrosis through alleviating mi2-200a 
inhibition of Smad 3 activity [95]. 
 
The collecting duct in diabetic nephropathy: a role for TGF-β1? 
 Until recently, EMT in the kidney was associated with more proximal regions of the nephron. 
However, pioneering studies by Butt et al utilizing a fetal primate model of obstructive nephropathy 
confirmed the capacity of those cells within the colletcing duct to undergo EMT [96]. Furthermore, 
both insulin growth factor 1 (IGF1) and TGF-β1 have been shown to induce classic EMT-like changes 
in mouse inner medullary collecting duct cells [97], despite initial studies suggesting that these cells 
could not undergo phenotypic conversion in response to TGF-β1 [98]. How TGF-β1 induced EMT 
contributes to fibrosis in the distal nephron is unclear. In 2009 Aldehni F et al. demonstrated that 
TGF-β1 induced EMT in the mouse renal collecting duct increased Bestrophin 1 (Best1), a protein 
known to regulate the concentration of  intracellular Ca
2+
 and increase cellular proliferation [99]. 
Suppression of Best1 by RNAi inhibited proliferation and down-regulated markers of EMT, 
suggesting that Best1 may function as a downstream mediator of TGF-β1 induced EMT and renal 
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fibrosis in the collecting duct. Deletion of the TβRII in cultured collecting duct cells evoked an 
increase in TGF-β activation with a subsequent exacerbation in renal fibrosis [100]. 
 TGF-β1 also promotes increased expression of the serum and glucocorticoid inducible kinase-
1 (SGK1), a serine/threonine kinase that regulates sodium re-absorption through control of the 
epithelial sodium channel (ENaC) [101-103]. SGK1 is elevated in models of diabetes [104], 
suggesting that it may contribute to the development of secondary hypertension. Interestingly SGK1 
is expressed in numerous tissues that exhibit fibrosis including cases of Crohn's disease, lung fibrosis, 
liver cirrhosis, fibrosing pancreatitis, DN and glomerulonephritis [105]. These studies suggest that 
SGK1 may also have a role in mediating the fibrotic effects of TGF-β1 in the collecting duct.  
 
THERAPEUTIC INTERVENTION 
 The pro-fibrotic actions of TGF-β -protective 
agents. Although TGF-β1 is regarded as the major isoform involved in fibrosis, improved renal 
function coincides with reduced expression of both TGF-β1 and TGF-β2 [106]. In the STZ-rat, renal 
expression of TGF-β2 is markedly increased and parallels ECM deposition in early stages of the 
disease [107]. By contrast, TGF-β1 protein levels remain unchanged during this initial period despite 
increased mRNA levels [107] Consequently, recent studies have focused on the antifibrotic potential 
of selectively targeting TGF-β2 for the prevention of progressive renal disease [108]. However, in 
diabetes, the pro-fibrotic role for all 3 isoforms [109] supports efforts to neutralize TGF-β1, TGF-β2 
or TGF-β3, to reduce renal scarring and improve overall kidney function [110]. Inhibition of TGF-β 
in this way also prevents glomerular enlargement and suppresses the expression of genes encoding for 
the ECM in models of chemically induced diabetes [110]. These findings were corroborated in db/db 
mice, where both TβRI and TβRII receptor mRNA expression were increased [111]. Chronic 
treatment of these animals with TGF-β-neutralizing antibodies markedly diminished the expression of 
collagen and fibronectin and reduced mesangial matrix expansion. Several anti-fibrotic and reno-
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protective agents have also been shown to partially alleviate TGF-β induced fibrosis including, Bone 
Morphogenic Protein-7 (BMP-7) and Hepatocyte Growth Factor (HGF). 
 An osteogenic factor, BMP-7 plays an important role in kidney development and regulation 
of nephrogenesis. Renal fibrosis in diabetes is inhibited by BMP-7. Following EMT, increased levels 
of TGF-β are paralleled by a reduction in expression of BMP-7, as a potential consequence of 
increased gremlin levels [112]. Gremlin limits BMP-7 availability and is markedly elevated in 
humans with DN [60]. This reciprocal relationship accounts for low BMP-7 concentrations in models 
of acute and chronic renal injury [113], and explains how exogenous BMP-7 restores renal function 
through blockade of EMT [114] Aside from the glomerular reno-protective effects observed in both 
STZ-rats and db/db mice, BMP-7 is capable of intercepting at the level of TGF-β signalling. In the 
adult, BMP-7 alleviates TGF-β-induced renal fibrosis [115] and antagonises TGF-β-induced Smad3-
dependent EMT [116]. However, the mechanism remains elusive since BMP-7 is unable to negate 
TGF-β-induced EMT in human PTC, suggesting that the effects are region specific [117]. The extent 
by which BMP-7 blocks EMT therefore requires further clarification. 
 A key anti-fibrotic cytokine, HGF prevents renal tissue fibrosis after chronic injury [118]. 
Administration of HGF reduces loss of kidney function, whilst blockade of HGF signalling further 
exacerbates the extent and progression of renal fibrosis [119]. As with BMP-7, HGF and TGF-β have 
a reciprocal relationship. HGF inhibits TGF-β-induced EMT, and ameliorates renal fibrotic lesions in 
numerous models of renal disease [119-120]. The underlying molecular mechanisms mediating these 
reno-protective effects are unknown. The anti-fibrotic activity of HGF appears to stem from up-
regulation of the transcriptional co-repressor SnoN. Binding of this co-repressor to Smad2 results in 
formation of a transcriptionally inactive complex, preventing the activation of Smad-mediated genes 
thereby blocking TGF-β-induced EMT [121]. Administration of HGF has been shown to alleviate 
renal complications in DN, including the reversal of glomerulosclerosis [122], a reduction in 
albuminuria [123] and blockade of fibrosis with a concomitant improvement in renal function [124]. 
However, a number of studies contradict these findings, suggesting that chronically elevated HGF 
promotes the progression of nephropathy in db/db mice [125]. Furthermore, potential proto-oncogenic 
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actions of HGF raises questions as to the potential therapeutic use of this growth factor in alleviating 
EMT induced complications in DN. Further studies are essential if HGF is to be considered as a future 
therapeutic means of intervening in fibrosis in DN. 
 Recent candidates identified upstream of HGF include, 9-cis retinoic acid, 1,25-
dihyrdoxyvitamin D3, the PPAR  agonist troglitazone and C-peptide [120-124][126]. A cleavage 
product of pro-insulin, C-peptide exerts a number of protective affects against the micro-vascular and 
macro-vascular complications associated with hyperglycaemia in type I diabetes [127] and in those 
patients with DN, C-peptide is reno-protective [128]. Recently, the Connecting-peptide has been 
shown to negate TGF-β induced EMT in cells of the proximal tubule [126] and as an adjunct to 
insulin therapy, C-peptide could be used to alleviate some renal complications of diabetes. However, 
like BMP-7 and HGF these findings are preliminary and whilst encouraging, need to be fully 
corroborated in the clinical scenario. 
 Studies of miRNA expression in diabetic nephropathy have predominantly been performed in 
animal models of diabetes and suggest that miRNAs may represent potential future therapeutic targets 
of renal fibrosis. Their role within the kidney appears to be region specific, e.g. miR-192 has been 
shown to exhibit elevated levels of expression in glomeruli isolated from the STZ mouse [129]. In this 
study, the function of miR-192 was shown to be of regulating repression of TGF-β1-induced changes 
in extracellular matrix proteins. Contrary to this, in proximal tubule cells reduced levels of mir-192 
have been described [93]. The loss of miR-192 has been shown to correlate with the degree of 
tubulointerstitial fibrosis in diabetic nephropathy. In Madin Darby canine kidney epithelial cells 
undergoing TGF-β1-induced EMT, a decrease in mir-200 and mir-205 suggests a link between 
miRNAs and the regulation of EMT [130]. Although these early studies suggest that miRNAs may 
represent reliable future biomarkers, the area of research demands considerable further attention,  
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Conclusion:  
 Although rigorous glycaemic control may reduce the burden of diabetes-associated morbidity, 
the Diabetes Control and Complications Trial (DCCT) showed that even with intensive insulin 
treatment, a substantial proportion of patients still develop complications. According to the 2007 
Renal Registry Report, diabetic nephropathy (DN) accounts for a significant proportion of the 40,000 
patients that require dialysis or transplantation in the UK each year and Worldwide, DN is the single 
commonest cause of entry into the renal replacement therapy programme. The increasing prevalence 
of diabetic nephropathy further highlights the urgency for discovery of  successful therapeutic agents 
aimed at alleviating renal fibrosis. TGF-β-induced EMT is a key contributor to fibrotic scar formation 
as seen in DN; therefore manipulating downstream TGF-β signalling represents a viable therapeutic 
target in an attempt to restore renal function. Administration of the anti-fibrotic growth factors HGF 
or BMP-7 can reverse the fibrogenic response and evidence supports the development of these types 
of reno-protective agents to alleviate complications of CKD, including DN. However, before a future 
treatment can ultimately arrest/reverse chronic kidney disease, further studies are required to fully 
understand how TGF-β1 exerts its plethoric effects. 
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FIGURE LEGENDS: 
Figure 1: Schematic depicting TGF-β1 signaling 
TGF-  binds to its type II serine/threonine kinase receptor and instigates autophophorylation 
permitting the recruitment of the type I receptor.  This interaction forms an activated heteromeric 
complex and facilitates phosphorylation of the receptor-regulated Smad2/3, promoting interaction 
with common Smad4. The active Smad2/3/4 complex translocates to the nucleus where it regulates 
the transcription of TGF- 1 target genes. TGF-β1 signaling is stringently regulated, and depends on 
both inhibitory Smads6/7 and transcriptional co-repressors that include SnoN, Ski, TGIF that help 
modify net cellular effects. 
 
Figure 2: Type 2-EMT in the kidney 
Loss in cell adhesion through the down-regulation of key epithelial markers, including E-cadherin 
(ECAD) and Zona-occludins (Zo-1), represents an initial step in type 2-EMT. Disassembly of the 
adherens junction complex is accompanied by a number of morphological and phenotypic changes. 
These gross changes are accompanied by alteration in the expression profile of key EMT proteins that 
include: up-regulation of vimentin, α-smooth muscle actin and fibroblast specific protein (FSP-1). 
Ultimately, cells detach from the tubular basement membrane (BM) and migrate into the interstitium 
where they exacerbate renal fibrosis. 
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